Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially....read more
In February, 10 IPOs raised a combined $2.0 billion, led by early debuts from a handful of $100+ million offerings. Deal flow was led by healthcare and senior facilities provider American Healthcare REIT (AHR) and Mexican discount grocer BBB Foods (TBBB),...read more
Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, raised $129 million by offering 8 million shares at $16, the high end of the range of $14 to $16. The company offered 1.3 million more shares than...read more
Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, announced terms for its IPO on Monday.The Los Altos, CA-based company plans to raise $101 million by offering 6.7 million shares at a price range of...read more
Biotech bust: 2024 biotech IPOs average a -52% return
Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially....read more
Renaissance Capital's February IPO Market Update
In February, 10 IPOs raised a combined $2.0 billion, led by early debuts from a handful of $100+ million offerings. Deal flow was led by healthcare and senior facilities provider American Healthcare REIT (AHR) and Mexican discount grocer BBB Foods (TBBB),...read more
CNS disorder biotech Alto Neuroscience prices upsized IPO at $16, the high end of the range
Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, raised $129 million by offering 8 million shares at $16, the high end of the range of $14 to $16. The company offered 1.3 million more shares than...read more
CNS disorder biotech Alto Neuroscience sets terms for $101 million IPO
Alto Neuroscience, a Phase 2 biotech developing biomarker-focused therapies for depression and schizophrenia, announced terms for its IPO on Monday.The Los Altos, CA-based company plans to raise $101 million by offering 6.7 million shares at a price range of...read more